Adrenomedullin (ADM) inhibits endothelial insulin signaling, contributing to obesity-associated insulin resistance, according ...

Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.

In nine out of ten patients with type 2 diabetes, severe obesity, known as adiposity, leads to diabetes. Type 2 diabetes is ...

In preliminary studies, we discovered that selected typical and atypical antipsychotic drugs interacted with virtually every biogenic amine receptor tested, in confirmation of many prior studies ...

Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes.

Q32 Bio (QTTB) announced a corporate restructuring to focus on the advancement of its bempikibart clinical development program for the ...

If insulin can’t get out of blood vessels, it can’t act in its target tissues. “Endothelial cells are full of insulin ...

Tivic Health Systems, Inc., today announced it has acquired worldwide exclusive license rights from Statera Biopharma to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimodtm for the ...

In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...

继在1月底公告全球首款眼科双抗Vabysmo在2024年大卖44亿美元，2月4日罗氏的Susvimo（100mg/mL雷珠单抗注射液）获得FDA的批准，用于治疗糖尿病性黄斑水肿（DME），眼科已经俨然成为了带动这家MNC业绩增长的“利剑”之一。

The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in ...

Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25; ...